Research: Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria
8 Mar, 2018 | 20:31h | UTCColistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial – The Lancet (link to abstract – $ for full-text)
“Combination therapy was not superior to monotherapy”.